Kelun-Biotech Unveils Promising Results for B7-H3 ADC SKB500 at ASCO 2026
Kelun-Biotech Presents First-in-human Study Data for Its Novel B7-H3 ADC SKB500 at ASCO 2026
Pr Newswire Apac
Image: Pr Newswire Apac
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. presented first-in-human study results for its B7-H3 antibody-drug conjugate SKB500 at the 2026 ASCO Annual Meeting. The study showed significant antitumor activity in various advanced solid tumors, particularly small cell lung cancer, with a favorable safety profile.
- 01The study enrolled 192 patients with advanced solid tumors, including small cell lung cancer, esophageal squamous cell carcinoma, and head and neck squamous cell carcinoma.
- 02At a dosage of 12 mg/kg, the objective response rate (ORR) was 42.7%, with a disease control rate (DCR) of 83.9% across multiple tumor types.
- 03Among small cell lung cancer patients, the ORR reached 65.0%, with a median progression-free survival of 7.2 months.
- 04The 12 mg/kg dosage exhibited a more favorable safety profile than the 16 mg/kg group, with a lower incidence of severe treatment-related adverse events.
- 05Kelun-Biotech is advancing to a Phase II exploratory study of SKB500 in combination with immunotherapy for extensive-stage small cell lung cancer.
Advertisement
In-Article Ad
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. unveiled promising first-in-human study results for its novel B7-H3 antibody-drug conjugate (ADC) SKB500. The study, led by Professor Liu Haifeng from Jilin Provincial Cancer Hospital, included 192 patients with advanced solid tumors, such as small cell lung cancer (SCLC) and esophageal squamous cell carcinoma (ESCC). Notably, SKB500 demonstrated an objective response rate (ORR) of 42.7% and a disease control rate (DCR) of 83.9% at a dosage of 12 mg/kg. Among SCLC patients, the ORR was 65.0%, with a median progression-free survival (mPFS) of 7.2 months. The 12 mg/kg dosage also showed a favorable safety profile, with a lower incidence of severe treatment-related adverse events compared to the 16 mg/kg group. These findings suggest SKB500's potential as a treatment option for aggressive tumors like SCLC, paving the way for further clinical studies.
Advertisement
In-Article Ad
The findings from this study may influence treatment protocols for advanced solid tumors, particularly small cell lung cancer, providing new hope for patients with limited options.
Advertisement
In-Article Ad
Reader Poll
What do you think about the potential of SKB500 as a treatment for advanced solid tumors?
Connecting to poll...
Read the original article
Visit the source for the complete story.